

## Scientific Programme

### Thursday, June 2, 2016

	AZIMUT (2 <sup>nd</sup> floor)	MUNICH (2 <sup>nd</sup> floor)	BERLIN (18 <sup>th</sup> floor)	MOSCOW (18 <sup>th</sup> floor)
07:30–18:00	REGISTRATION		REGISTRATION	
08:30–09:00	<b>Introduction</b> R. Ceska (Czech Republic) Y. Matsuzawa (Japan) P. Barter (Australia) E. Shlyakhto (Russia) M. Ezhov (Russia)			
09:00–09:45	<b>Guidelines LDL -C and HDL-C</b> C. M. Ballantyne (USA) P. Barter (Australia)			
09:45–11:00	<b>Familial hypercholesterolemia</b> G. Watts (Australia) R. Ceska (Czech Republic)		<b>INDUSTRY SPONSORED SYMPOSIUM</b> 	
11:00–11:30	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK
11:30–12:45	<b>Metabolic syndrome atherogenic DLP</b> Y. Matsuzawa (Japan) A. Zambon (Italy)	<b>Lp(a)</b> H. N. Ginsberg (USA) M. Ezhov (Russia)	<b>Pediatric aspects of familial hypercholesterolemia (FH): the basic concept of atherogenesis</b> K. Widhalm (Austria) C. Stefanutti (Italy)	<b>Genetics &amp; Biomarkers</b> M. Holmes (United Kingdom) Y. Timasheva (Russia)
12:45–14:00	LUNCH BREAK	<b>INDUSTRY SPONSORED SYMPOSIUM (page 34)</b>	LUNCH BREAK	LUNCH BREAK
14:00–15:15	<b>Clinical lipidology</b> K. Parhofer (Germany) M. Banach (Poland)	<b>Epidemiology</b> Ch. Park (South Korea) I. Pecin (Croatia)	<b>INDUSTRY SPONSORED SYMPOSIUM</b> 	<b>Treatment of HLP &amp; Familial hypercholesterolemia &amp; Metabolic syndrome</b> M. Voevoda (Russia) M. Wang (USA)
15:15–16:30	<b>Hypertension I</b> P. M. Nilsson (Sweden) A. Konradi (Russia)	<b>Statin intolerance</b> E. Bruckert (France) T. Stulc (Czech Republic)		<b>Metabolic syndrome I</b> G. Belakova (Slovakia) D. Hasnani (India)
16:30–16:45	COFFEE BREAK	COFFEE BREAK		COFFEE BREAK
16:45–17:20	<b>Diabetes</b> K. Raslova (Slovakia) M. Prazny (Czech Republic)	<b>Smoking cessation</b> R. Puri (India)		<b>Biomarkers &amp; Genetics</b> D. Abdalla (Brazil) T. Fedotova (USA)
17:20–18:00		<b>Indian lipid guidelines</b> E. Kralikova (Czech Republic)		

Thursday, June 2, 2016

Friday, June 3, 2016

Saturday, June 4, 2016

## Meeting Hall AZIMUT (2<sup>nd</sup> floor)

- 08:30–09:00 Introduction**  
R. Ceska (Czech Republic), Y. Matsuzawa (Japan), P. Barter (Australia), E. Shlyakhto (Russia), M. Ezhov (Russia)
- 09:00–09:45 Guidelines LDL-C and HDL-C**  
C. M. Ballantyne (USA), P. Barter (Australia)
- 09:00–09:20 Is there sufficient evidence to include HDL as a target in lipid guidelines?**  
P. Barter (Australia)
- 09:20–09:40 LDL-C as main factor for CVD**  
C. M. Ballantyne (USA)
- 09:40–09:45 General discussion**
- 09:45–11:00 Familial hypercholesterolemia**  
G. Watts (Australia), R. Ceska (Czech Republic)
- 09:45–10:10 Introduction**  
G. Watts (Australia), R. Ceska (Czech Republic)
- 10:10–10:35 The 10 Countries FH Study: opportunities for international networks**  
G. Watts (Australia)
- 10:35–11:00 50 years of FH in Czech Republic**  
R. Ceska (Czech Republic)
- 11:00–11:30 Coffee break**
- 11:30–12:45 Metabolic syndrome atherogenic DLP**  
Y. Matsuzawa (Japan), A. Zambon (Italy)
- 11:30–12:00 Metabolic syndrome-contribution of visceral fat and adiponectin**  
Y. Matsuzawa (Japan)
- 12:00–12:30 Treatment of atherogenic DLP**  
A. Zambon (Italy)
- 12:30–12:45 General discussion**
- 12:45–14:00 Lunch break**
- 14:00–15:15 Clinical lipidology**  
K. Parhofer (Germany), M. Banach (Poland)
- 14:00–14:25 Secondary hyperlipidemias: An overview**  
K. Parhofer (Germany)
- 14:25–14:50 Combination therapy in dyslipideamic patients - the current state of knowledge (2016)**  
M. Banach (Poland)
- 14:50–15:15 General discussion**
- 15:15–16:30 Hypertension I**  
P. M. Nilsson (Sweden), A. Konradi (Russia)
- 15:15–15:40 Assessment of target organ damage in hypertension. Focus on large arteries.**  
A. Konradi (Russia)
- 15:40–16:05 Blood pressure goals in hypertension and varying cardiovascular risk**  
P. M. Nilsson (Sweden)
- 16:05–16:30 Renal denervation and its role in resistant hypertension**  
J. Widimsky (Czech Republic)
- 16:30–16:45 Coffee break**

- 16:45–18:00** **Diabetes**  
K. Raslova (Slovakia), M. Prazny (Czech Republic)
- 16:45–17:10** **New oral antidiabetic drugs**  
M. Prazny (Czech Republic)
- 17:10–17:35** **Treatment of diabetes and its effect on body weight**  
K. Raslova (Slovakia)
- 17:35–18:00** **General discussion**

## Meeting Hall MUNICH (2<sup>nd</sup> floor)

- 11:30–12:45** **Lp(a)**  
H. N. Ginsberg (USA), M. Ezhov (Russia)
- 11:30–11:55** **The effects of drugs on Lp(a) metabolism: studies with stable isotopes**  
H. N. Ginsberg (USA)
- 11:55–12:20** **What do we know about Lp(a) atherogenicity? Moscow experience since 1987**  
M. Ezhov (Russia)
- 12:20–12:45** **Apheresis as a treatment option for elevated Lp(a)**  
K. Parhofer (Germany)
- 12:45–14:00** **Industry Sponsored Symposium**  
(For detailed programme see page 34)
- 14:00–15:15** **Epidemiology**  
Ch. Park (South Korea), I. Pecin (Croatia)
- 14:00–14:15** **Prevalence and clinical features of diabetes and prediabetes in patients with hypertension in Korea: a nationwide community study**  
Ch. Park (South Korea)
- 14:15–14:30** **High prevalence of metabolic syndrome in rural part of Croatia: Croatian rural study**  
I. Pecin (Croatia)
- 14:30–14:40** **The 4-year follow-up of medications compliance in patients after elective percutaneous coronary intervention with drug-eluting stent (data from OPTIMA II study)**  
Y. Khomitskaya (Russia)
- 14:40–14:50** **Analysis of the prevalence of hypercholesterolemia in the outpatient practice (according to the ARGO study)**  
N. Akhmedzhanov (Russia)
- 14:50–15:00** **Lipoprotein (a) and apolipoprotein (a) phenotypes in healthy Macedonian children**  
K. Tosheska-Trajkovska (Macedonia)
- 15:00–15:15** **General discussion**
- 15:15–16:30** **Statin intolerance**  
E. Bruckert (France), M. Banach (Poland)
- 15:15–15:45** **Statin intolerance in 2016 - definition, pathomechanism, biomarkers, management, prevention**  
M. Banach (Poland)
- 15:45–16:15** **Outline of the EAS consensus statement on SAMS**  
E. Bruckert (France)
- 16:15–16:30** **General discussion**
- 16:30–16:45** **Coffee break**
- 16:45–17:20** **Smoking cessation**  
R. Puri (India)
- 16:45–17:05** **Smoking patient in daily practice**  
E. Kralikova (Czech Republic)
- 17:05–17:20** **General discussion**
- 17:20–18:00** **Indian lipid guidelines**  
E. Kralikova (Czech Republic)
- 17:20–17:40** **Expert consensus statement on management of dyslipidemia in Indians 2016**  
R. Puri (India)
- 17:40–18:00** **General discussion**

## Meeting Hall BERLIN (18<sup>th</sup> floor)

- 09:45–11:00  **Industry Sponsored Symposium**
- 11:00–11:30 **Coffee break**
- 11:30–12:45 **Pediatric aspects of familial hypercholesterolemia (FH): the basic concept of atherogenesis**  
K. Widhalm (Austria), C. Stefanutti (Rome)
- 11:30–11:50 **The development of atherosclerosis during childhood on the example of FH**  
A. Wiegman (Netherlands)
- 11:50–12:10 **Dietary effects and 35 yrs experience with 9 children with hoFH**  
K. Widhalm (Austria)
- 12:10–12:35 **Lipoprotein apheresis in the treatment of severe hoFH children: current state and future perspectives**  
C. Stefanutti (Italy)
- 12:35–12:45 **General discussion**
- 12:45–14:00 **Lunch break**
- 14:00–15:15  **Industry Sponsored Symposium**

## Meeting Hall MOSCOW (18<sup>th</sup> floor)

- 11:30–12:45 **Genetics & Biomarkers**  
M. Holmes (United Kingdom), Y. Timasheva (Russia)
- 11:30–11:38 **Cytokine gene polymorphisms impact healthy life expectancy and coronary heart disease**  
V. Erdman (Russia)
- 11:38–11:46 **Presence of cardiovascular disease and telomere length in middle-aged and older Russians**  
M. Holmes (United Kingdom)
- 11:46–11:54 **Modern estimation of hypolipidemic efficiency of inhibitors of synthesis of cholesterol by means of pharmacogenetical markers for patients by ischemic heart disease and hyperlipidemias**  
G. Mal (Russia)
- 11:54–12:02 **Dynamics of subclinical carotid atherosclerosis and telomere length in ageing population**  
A. Ryabikov (Russia)
- 12:02–12:10 **Gene-gene interactions affecting the risk of myocardial infarction in two populations from Russia**  
Y. Timasheva (Russia)
- 12:10–12:18 **The modern concept of the atherosclerosis mechanisms: The role of the innate immunity**  
N. Tsygan (Russia)
- 12:18–12:26 **Association of circulating endothelial cells and flow-dependent vasodilatation with recurrent cardiovascular events after acute myocardial infarction**  
A. Philippov (Russia)
- 12:26–12:34 **New biomarkers in risk stratification of kidney injury in patients with acute coronary syndrome**  
I. Vishnevskaya (Ukraine)
- 12:34–12:45 **General discussion**
- 12:45–14:00 **Lunch break**

- 14:00–15:15** **Treatment of HLP & Familial hypercholesterolemia & Metabolic syndrome**  
M. Voevoda (Russia), M. Wang (USA)
- 14:00–14:08** **Comparative analysis of the lipid profile in women with CHD with androgenic component**  
F. Gasimova (Azerbaijan)
- 14:08–14:16** **Anti-inflammatory and anti-atherogenic effects of the inflammasome NLRP3 inhibitor, arglabin, in ApoE2.Ki mice fed a high fat diet**  
M. Rouis (France)
- 14:16–14:24** **Hypolipidemic effects of a novel compound in an animal model of hypercholesterolemia (WHHLM1 rabbits)**  
M. Shiomi (Japan)
- 14:24–14:32** **Myocardial infarction regional register use for targeted screening of familial hypercholesterolemia**  
R. Khokhlov (Russia)
- 14:32–14:40** **Do lipid peroxidation products contribute to atherosclerotic calcification?**  
S. Parthasarathy (USA)
- 14:40–14:48** **Analysis of lipid metabolism genes variability in patients with familial hypercholesterolemia in Russia using targeted high throughput resequencing**  
M. Voevoda (Russia)
- 14:48–14:56** **Incidence of hypercholesterolemia and other cardiovascular risk factors according to ESSE-RF research in West Siberia**  
A. Kochergina (Russia)
- 14:56–15:04** **Aging and diet interactions in atherogenesis of nonhuman primates**  
M. Wang (USA)
- 15:04–15:15** **General discussion**
- 15:15–16:30** **Metabolic syndrome I**  
G. Belakova (Slovakia), D. Hasnani (India)
- 15:15–15:25** **GQ-11: A novel PPAR $\alpha$  agonist with beneficial effects in high fat diet-induced obesity**  
D. Abdalla (Brazil)
- 15:25–15:35** **Metabolic syndrome and inflammatory connective tissue diseases**  
G. Belakova (Slovakia)
- 15:35–15:45** **The parameters of ambulatory blood pressure monitoring and endothelial dysfunction in hypertensive patients with diabetes mellitus type 2**  
M. Derevyanchenko (Russia)
- 15:45–15:55** **Free but not total testosterone is inversely correlated with subclinical atherosclerosis in type 2 diabetic men**  
E. Faludi (Brazil)
- 15:55–16:05** **Flow Mediated Dilatation (FMD) score as an effective tool for screening of CVD in T2DM**  
D. Hasnani (India)
- 15:05–16:15** **Effectiveness of different treatment of metabolic syndrome**  
N. Vinogradova (Russia)
- 16:15–16:25** **Cholesterol level or age is more powerful in subclinical atherosclerosis progression during 2-years follow-up of relatively healthy bank employers?**  
O. Rotar (Russia)
- 16:25–16:30** **General discussion**
- 16:30–16:45** **Coffee break**

- 16:45-18:00**    **Biomarkers & Genetics**  
D. Abdalla (Brazil), T. Fedotova (USA)
- 16:45-16:53**    **New peptide-based radiotracer for atherosclerosis PET imaging**  
D. Abdalla (Brazil)
- 16:53-17:01**    **Antibodies against C-Reactive Protein, CRP peptide and 60-Kilodalton Heat Shock Proteins in patients with Acute coronary atherothrombosis**  
I. Burazor (Serbia)
- 17:01-17:09**    **Lipoprotein (a) in acute coronary atherothrombosis**  
I. Burazor (Serbia)
- 17:09-17:17**    **Two measurements of brain natriuretic peptide levels in acute myocardial infarction improve risk prediction of recurrent events in the short-term compared to grace score: A Brasilia heart study subanalysis**  
L. S. Carvalho (Brazil)
- 17:17-17:25**    **Association of osteopontin level with coronary atherosclerosis and osteoporosis in man with stable coronary artery disease**  
V. Kashtalap (Russia)
- 17:25-17:33**    **Leukocyte telomere length in peripheral blood as ageing marker and risk factors for age-related diseases in humans**  
V. Maximov (Russia)
- 17:33-17:41**    **Alterations in lipid transfers to High Density Lipoprotein (HDL) in patients with Heart Failure**  
R. Maranhao (Brazil)
- 17:41-17:49**    **Inhibition of apoB+DGAT2 synthesis using antisense oligonucleotides rescues liver steatosis**  
T. Fedotova (USA)
- 17:49-18:00**    **General discussion**


Thursday, June 2, 2016



Friday, June 3, 2016

Saturday, June 4, 2016

## Friday, June 3, 2016

	AZIMUT (2 <sup>nd</sup> floor)	MUNICH (2 <sup>nd</sup> floor)	BERLIN (18 <sup>th</sup> floor)	MOSCOW (18 <sup>th</sup> floor)
07:30–18:00	REGISTRATION		REGISTRATION	
08:30–09:45	<b>Lipid apheresis</b> S. Pokrovsky (Russia) U. Julius (Germany)	<b>Monogenic dyslipideamias in children: from diagnosis to management</b> A. V. Susekov (Russia)	<b>INDUSTRY SPONSORED SYMPOSIUM</b> 	<b>Varia</b> R. Fraser (New Zeland) A. Tselepis (Greece)
09:45–11:00	<b>Pharmacological treatment</b> J. J. P. Kastelein (Netherlands) T. Stulc (Czech Republic)	<b>FH activities I Ten countries study</b> G. Watts (Australia)	<b>INDUSTRY SPONSORED SYMPOSIUM</b> 	<b>“From everyday clinical practice”</b> B. O. Kim (Korea) B. Tomlinson (Hong Kong)
11:00–11:30	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK
11:30–12:45	<b>How to implement the knowledge of CVD risk in patients with RA into clinical practice</b> T. R. Pedersen (Norway) J. J. P. Kastelein (Netherlands)	<b>FH activities II ScreenPro FH</b> R. Ceska (Czech Republic) G. Paragh (Hungary)	<b>INDUSTRY SPONSORED SYMPOSIUM</b> 	<b>Epidemiology</b> A. Leiharer (Austria) N. Polenova (Russia)
12:45–14:00	<b>INDUSTRY SPONSORED SYMPOSIUM (page 34)</b>	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK
14:00–15:15	<b>R3i (14:30–15:30)</b> J.-C. Fruchart (France) K. Al-Rasadi (Oman)	<b>ScreenPro FH – Workshop</b> R. Ceska (Czech Republic) G. Paragh (Hungary)	<b>INDUSTRY SPONSORED SYMPOSIUM</b> 	<b>Epidemiology &amp; Cardiology/ Hypertension &amp; Varia</b> O. Afanasieva (Russia) O. Gaydukova (Russia)
15:15–16:30	<b>Stroke (15:30–16:30)</b> M. Vrablik (Czech Republic)	<b>Clinical trials</b> T. R. Pedersen (Norway) R. Carmena (Spain)		<b>Cardiology/ Hypertension</b> E. Gerasimova (Russia) V. Kolomiyets (Ukraine)
16:30–16:45	COFFEE BREAK	COFFEE BREAK		COFFEE BREAK
16:45–18:00	<b>Non pharmacological treatment of HLP and DLP</b> T. Stulc (Czech Republic) A. Orlov (Russia)	<b>Emerging lipid risk factors</b> A. Tselepis (Greece)		<b>Metabolic syndrome II</b> A. Leiharer (Austria) R. Lijnen (Belgium)

Thursday, June 2, 2016

Friday, June 3, 2016

Saturday, June 4, 2016

## Meeting Hall AZIMUT (2<sup>nd</sup> floor)

- 08:30–09:45**    **Lipid apheresis**  
S. Pokrovsky (Russia), U. Julius (Germany)
- 08:30–09:00**    **Lipid apheresis. An overview**  
S. Pokrovsky (Russia)
- 09:00–09:25**    **Characterization of patients who started or stopped a lipoprotein apheresis (LA) at our center in 2014 and 2015**  
U. Julius (Germany)
- 09:25–09:35**    **Early use of therapeutic apheresis reduces the incidence of angiographic in-stent restenosis and major cardiovascular events in patients with stable coronary artery disease after coronary stenting**  
V. Tishko (Russia)
- 09:35–09:45**    **Familial hypercholesterolemia (FH): Efficiency and safety of the treatment by LDL aphaeresis: “Lebanese experience”**  
E. Moubarak (Lebanon)
- 09:45–11:00**    **Pharmacological treatment**  
J. J. P. Kastelein (Netherlands), T. Stulc (Czech Republic)
- 09:45–10:15**    **Novel developments in the pharmacological treatment of dyslipidemia**  
J. J. P. Kastelein (Netherlands)
- 10:15–10:25**    **Lomitapide in familial chylomicronemia**  
T. Stulc (Czech Republic)
- 10:25–10:35**    **The role of aggressive statin therapy on morphological changes of venous grafts in patients after surgical myocardial revascularisation**  
A. Panov (Russia)
- 10:35–10:45**    **Effectiveness of Mipomersen compared to Alirocumab for Heterozygous familial hypercholesterolemia**  
P. Moriarty (USA)
- 10:45–11:00**    **General discussion**
- 11:00–11:30**    **Coffee break**
- 11:30–13:00**    **How to implement the knowledge of CVD risk in patients with RA into clinical practice**  
T. R. Pedersen (Norway), J. J. P. Kastelein (Netherlands)
- 11:30–11:55**    **Cardiovascular risk evaluation and CVD in patients with RA**  
A. G. Semb (Norway)
- 11:55–12:20**    **Impact of anti-rheumatic treatment on CVD in RA**  
P. van Riel (Netherlands)
- 12:20–12:45**    **Management of CV risk and disease in RA**  
Silvia Rollefstad (Norway)
- 12:45–13:00**    **Guidelines for CVD prevention in inflammatory joint diseases**  
T. R. Pedersen (Norway)
- 13:00–14:30**    **Industry Sponsored Symposium**  
*(For detailed programme see page 34)*



- 14:30–15:30 R3i**  
J.-C. Fruchart (France), K. Al-Rasadi (Oman)
- 14:30–14:55 SPPARM $\alpha$  at the crossroads of obesity, diabetes and cardiovascular diseases**  
J.-C. Fruchart (France)
- 14:55–15:20 Management of hypertriglyceridemia (current and future)**  
K. Al-Rasadi (Oman)
- 15:20–15:30 Panel discussion**
- 15:30–16:30 Stroke**  
M. Vrablik (Czech Republic)
- 15:30–15:55 Lipid lowering in stroke prevention: why and how**  
M. Vrablik (Czech Republic)
- 15:55–16:10 The clinical impact of atherothrombosis in atrial fibrillation**  
F. Violi (Italy)
- 16:10–16:20 The features of atrial fibrillation in patients with myocardial infarction**  
N. Neobutov (Russia)
- 16:20–16:30 Rationality and immediate results for the use of the rheolytic thrombectomy (AngioJet) in patients with STEMI**  
M. Malhasyan (Russia)
- 16:30–16:45 Coffee break**
- 16:45–18:00 Non pharmacological treatment of HLP and DLP**  
T. Stulc (Czech Republic), A. Orlov (Russia)
- 16:45–16:55 The association of nut consumption with cardiovascular mortality and coronary heart disease risk in women**  
T. Imran (USA)
- 16:55–17:05 Physical activity monitoring in population-based sample of Saint Petersburg inhabitants**  
A. Orlov (Russia)
- 17:05–17:15 The Mediterranean diet improve n-3 fatty acids index and eicosanoids profile among former athletes in comparison to caloric restriction diet (CR)**  
D. Maciejewska (Poland)
- 17:15–17:25 Effects of physical exercises on WAT characteristics in DIO rats**  
I. Yakimovich (Russia)
- 17:25–17:35 Effects of Chios mastic gum on cholesterol and glucose levels of hyperlipidemic, prediabetic, overweight volunteers**  
A. Kartalis (Greece)
- 17:35–18:00 General discussion**

## Meeting Hall MUNICH (2<sup>nd</sup> floor)

- 08:30–09:45 Monogenic dyslipideamias in children: from diagnosis to management**  
A. V. Susekov (Russia)
- 08:30–09:00 Lipid disorders in CKD patients: the road map to clinicians**  
A. V. Susekov (Russia)
- 09:00–09:30 Patient with homozygous FH: crossroads of diagnosis and management**  
V. Soloviev (Russia)
- 09:30–09:45 General discussion**
- 09:45–11:00 FH activities I**  
**Ten countries study**  
G. Watts (Australia)
- 11:00–11:30 Coffee break**
- 11:30–12:45 FH activities II**  
**ScreenPro FH**  
R. Ceska (Czech Republic), G. Paragh (Hungary)
- 12:45–14:00 Lunch break**

- 14:00–15:15** **ScreenPro FH - Workshop**  
R. Ceska (Czech Republic), G. Paragh (Hungary)
- 14:00–14:15** **ScreenPro FH development**  
R. Ceska (Czech Republic)
- 14:15–14:35** **FH in the Czech Republic: Data from a nationwide database**  
T. Freiburger (Czech Republic)
- 14:35–14:50** **The development of FH screening in Hungary**  
G. Paragh (Hungary)
- 14:50–15:00** **The prevalence of heterozygous familial hypercholesterolemia in the West Siberian region of the Russian Federation**  
A. Ershova (Russia)
- 14:00–15:10** **Familial hypercholesterolemia: Cascade screening diagnostic impact, a case report**  
A. Rocha (Brazil)
- 15:10–15:15** **General discussion**
- 15:15–16:30** **Clinical trials**  
T. R. Pedersen (Norway), R. Carmena (Spain)
- 15:15–15:40** **Lipid lowering in the light of clinical trials. From „4S“ to the future**  
T. R. Pedersen (Norway)
- 15:40–16:05** **Why Ezetimibe did better in diabetics in the IMPROVE-IT TRIAL**  
R. Carmena (Spain)
- 16:05–16:30** **VARO, VATARO and ATTRACTIVE – trials from everyday practice**  
R. Ceska (Czech Republic)
- 16:30–16:45** **Coffee break**
- 16:45–18:05** **Emerging lipid risk factors**  
A. Tselepis (Greece)
- 16:45–17:05** **Lipoprotein-associated phospholipase A2 as an important determinant of lipoprotein-mediated cardiovascular risk**  
A. Tselepis (Greece)
- 17:05–17:15** **Is lipoprotein associated phospholipase A2 an early markers of cardiac damage in rheumatoid arthritis patients without ischemic heart disease?**  
J. Lietava (Slovakia)
- 17:15–17:25** **Integrated biomarkers and coronary atherosclerosis: which path to take?**  
N. Gavrilova (Russia)
- 17:25–17:35** **Low cytochrome oxidase in monocytes and monocyte-derived exosomes 1 links mitochondrial dysfunction to incident cardiovascular diseases**  
P. Holvoet (Belgium)
- 17:35–17:45** **Plasmatic and urinary microRNAs as biomarkers in cardiovascular diseases**  
J. Novak (Czech Republic)
- 17:45–17:55** **Multiple modification of LDL**  
A. Orekhov (Russia)
- 17:55–18:05** **High neutrophil and basophil blood counts are associated with an increased factor II plasma coagulant activity and may predict total and cardiovascular mortality in patients with stable coronary artery disease**  
N. Martinelli (Italy)

## Meeting Hall BERLIN (18<sup>th</sup> floor)

- 08:30–09:45**  **Industry Sponsored Symposium**  
(For detailed programme see page 35)
- 09:45–11:00**  **Industry Sponsored Symposium**  
(For detailed programme see page 35)
- 11:00–11:30** **Coffee break**
- 11:30–12:45**  **Industry Sponsored Symposium**  
(For detailed programme see page 36)
- 12:45–14:00** **Lunch break**
- 14:00–15:15**  **Industry Sponsored Symposium**  
(For detailed programme see page 36)

## Meeting Hall MOSCOW (18<sup>th</sup> floor)

- 08:30–09:45** **Varia**  
R. Fraser (New Zealand), A. Tselepis (Greece)
- 08:30–08:38** **Anitschkow's expanding legacy: Porosity of the "Liver Sieve" influences Atherosclerosis and many other Maladies**  
R. Fraser (New Zealand)
- 08:38–08:46** **Arterial stiffness in rheumatoid arthritis and coronary artery disease**  
L. Krougly (Russia)
- 08:46–08:54** **Clinical features and risk factors of coronary artery diseases in rheumatoid arthritis**  
L. Krougly (Russia)
- 08:54–09:02** **Immunopatological mechanisms of the destabilization of atherosclerotic plaque by human**  
P. Pigarevsky (Russia)
- 09:02–09:10** **Anitschkow's ideas today**  
E. Protasov (Russia)
- 09:10–09:18** **Clopidogrel binds to lipoprotein-associated phospholipase A2 (Lp-PLA2) and inhibits the enzyme activity in patients with an acute coronary syndrome**  
A. Tselepis (Greece)
- 09:18–09:26** **Implementation of the Treat-to-Target strategy in early rheumatoid arthritis patients could not prevent an atherosclerosis progression in carotid arteries**  
E. Udachkina (Russia)
- 09:26–09:34** **Anti-atherogenic role of c-Kit/SCF signaling in hyperlipidemic mice**  
R. Vazquez-Padron (USA)
- 09:34–09:45** **General discussion**
- 09:45–11:00** **"From everyday clinical practice"**  
B. O. Kim (Korea), B. Tomlinson (Hong Kong)
- 09:45–09:53** **The obesity-mortality paradox in the patients with peripheral artery disease undergoing lower extremity endovascular intervention**  
B. O. Kim (Korea)
- 09:53–10:01** **The elderly with STEMI are more likely to have normal lipid level**  
A. Kochergina (Russia)
- 10:01–10:09** **Are statins indicated for therapy of resistant hypertension? Lessons of NEMESYS study**  
V. Kosmalova (Slovakia)
- 10:09–10:17** **Comparison of Multiplate analyser measurement and serum thromboxane B2 concentrations to assess the platelet response to low-dose aspirin in Chinese patients with coronary artery disease**  
B. Tomlinson (Hong Kong)
- 10:17–10:25** **High incidence of asymptomatic PAD among unselected patients**  
C. Zara (Romania)
- 10:25–10:33** **Elevated lipoprotein (a) (Lp (a)) levels and aggressive coronary heart disease (CHD): A casuistic approach**  
A. Dybvig (Hungary)
- 10:33–10:41** **Patient-centered care for cardiovascular disease primary prevention in elderly patient**  
M. Gertsen (Belarus)
- 10:41–10:49** **Absence of the posterior mitral valve leaflet detected in late adulthood**  
B. Kalaycı (Turkey)
- 10:49–11:00** **General discussion**
- 11:00–11:30** **Coffee break**

- 11:30–12:45**    **Epidemiology**  
A. Leisherer (Austria), N. Polenova (Russia)
- 11:30–11:38**    **Long-term risk of arterial hypertension and stroke in women aged 25–64 years with sleep disturbances in Russia/Siberia: based on WHO epidemiological program MONICA-psychosocial**  
V. Gafarov (Russia)
- 11:38–11:46**    **Analysis of detection rate of carotid atherosclerosis in the Russian population**  
O. Gaisenok (Russia)
- 11:46–11:54**    **Hemodynamic parallels between erectile dysfunction and diastolic dysfunction of left ventricle**  
S. Krasnyak (Russia)
- 11:54–12:02**    **Diabetes awareness among coronary artery disease patients differs significantly between men and women**  
A. Leisherer (Austria)
- 12:02–12:10**    **How important is health for young people? – The health care scales' results among young participants of Woodstock Festival Poland**  
D. Maciejewska (Poland)
- 12:10–12:18**    **Carotid plaques, intima-media thickening and 10-year risk of cardiovascular outcomes and mortality in a Russian population sample**  
S. Malyutina (Russia)
- 12:18–12:26**    **Comparison of lipid profile of 617 professional ice hockey players with non-athletes**  
N. Polenova (Russia)
- 12:26–12:34**    **Current cardiovascular risk factors estimate in a representative population of Casablanca (Morocco)**  
R. Saile (Morocco)
- 12:34–12:45**    **General discussion**
- 12:45–14:00**    **Lunch break**
- 14:00–15:15**    **Epidemiology & Cardiology/Hypertension & Varia**  
O. Afanasieva (Russia), O. Gaydukova (Russia)
- 14:00–14:12**    **The low molecular weight apolipoprotein(a) phenotype as the important risk factor for coronary atherosclerosis**  
O. Afanasieva (Russia)
- 14:12–14:24**    **The Impact of existent cardiovascular diseases, traditional risk factors, systemic inflammation on N-Terminal pro-brain natriuretic peptide level in patients with early rheumatoid arthritis**  
I. Kirillova (Russia)
- 14:24–14:36**    **Notch signaling is differently altered in smooth muscle and endothelial cells of thoracic aortic aneurysm patients**  
D. Kostina (Russia)
- 14:36–14:48**    **Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis, results of 10-year prospective controlled single-center study**  
I. Gaydukova (Russia)
- 14:48–15:00**    **The causes of termination of therapy: Survey of patients of cardiological hospitals of Saratov and the small city of Saratov region**  
E. Naumova (Russia)
- 15:00–15:15**    **General discussion**

- 15:15–16:30** **Cardiology/Hypertension**  
E. Gerasimova (Russia), V. Kolomiyets (Ukraine)
- 15:15–15:23** **Lipid profile in patients with diabetes with a left main coronary artery stenosis**  
A. Galyavich (Russia)
- 15:23–15:31** **Risk factors of coronary artery stenosis in patients with rheumatoid arthritis**  
E. Gerasimova (Russia)
- 15:31–15:39** **Relationship between traditional factors of cardiovascular risk and subclinical carotid atherosclerosis**  
A. Golovina (Russia)
- 15:39–15:47** **How well does the contemporary primary prevention strategy identify patients at risk: comparison with the results of carotid atherosclerosis imaging**  
N. Katamadze (Russia)
- 15:47–15:55** **The influence of atorvastatin on endothelium dysfunction and combined course of ischemic heart disease, essential hypertension and chronic obstructive pulmonary disease**  
V. Kolomiyets (Ukraine)
- 15:55–16:03** **The level of cardiovascular risk factors correction in patient undergoing myocardial revascularization**  
E. Lubinskaya (Russia)
- 16:03–16:11** **Statins for the prevention of early postoperative cognitive dysfunction in patients undergoing coronary artery bypass grafting**  
O. Maleva (Russia)
- 16:11–16:19** **Association of Pro12Ala polymorphism of PPAR-gamma2 gene with insulin resistance and coronary artery disease in Russia**  
E. Sergeeva (Russia)
- 16:19–16:30** **General discussion**
- 16:30–16:45** **Coffee break**
- 16:45–18:00** **Metabolic syndrome II**  
A. Leiherer (Austria), R. Lijnen (Belgium)
- 16:45–16:55** **The intensity of metabolic alterations and the results of reconstructive interventions in patients with widespread atherosclerosis**  
K. Khisamova (Russia)
- 16:55–17:05** **Coronary artery disease as a risk for developing type 2 diabetes mellitus**  
A. Leiherer (Austria)
- 17:05–17:15** **Effect of ADAMTS5 deficiency on the metabolic syndrome**  
R. Lijnen (Belgium)
- 17:15–17:25** **Relationships between lipid parameters and liver markers in men with type 2 diabetes mellitus, non-alcoholic fatty liver disease and stable ischaemic heart disease, atherosclerosis of the aorta**  
V. Matveev (Russia)
- 17:25–17:35** **Metabolic syndrome complicated by coronary atherosclerosis in Arctic Circle, for example the Yakutian population: ethnicity and gender differences**  
A. Romanova (Russia)
- 17:35–17:45** **Prevalence of low Testosterone among T2DM patients: symptomatic vs asymptomatic population for sexual dysfunction**  
B. Saboo (India)
- 17:45–17:55** **Blood lipids and coronary stenosis in patients with type 2 diabetes undergoing trans-femoral amputation in different clinical groups**  
E. Shalaeva (Uzbekistan)
- 17:55–18:00** **General discussion**

## Saturday, June 4, 2016

	AZIMUT (2 <sup>nd</sup> floor)	MUNICH (2 <sup>nd</sup> floor)
08:30–13:00	<b>REGISTRATION</b>	
09:00–10:00	<b>Hypertension II</b> R. Cifkova (Czech Republic) A. Rynkiewicz (Poland)	<b>Symposium of the international task force for prevention of cardiometabolic diseases (Diabetes and Atherosclerosis: New Translational Aspects)</b> G. Assmann (Germany) H. Greten (Germany)
10:00–11:00	<b>Obesity</b> A. Cuevas (Chile) Z. Fras (Slovenia)	
11:00–11:15	<b>COFFEE BREAK</b>	
11:15–12:15	<b>Genetics</b> M. Vrablik (Czech Republic) M. Voevoda (Russia)	<b>Hot lines</b> R. Ceska (Czech Republic)
12:15–12:30	<b>Closing</b> R. Ceska (Czech Republic) Y. Matsuzawa (Japan) P. Barter (Australia) E. Shlyakhto (Russia) M. Ezhov (Russia)	

### Meeting Hall AZIMUT (2<sup>nd</sup> floor)

- 09:00–10:00 **Hypertension II**  
 R. Cifkova (Czech Republic), A. Rynkiewicz (Poland)
- 09:00–09:20 **The history of optimal blood pressure targets in atherothrombotic events prevention**  
 A. Rynkiewicz (Poland)
- 09:20–09:40 **Hypertension and Stroke**  
 R. Cifkova (Czech Republic)
- 09:40–09:50 **Plasma renin activity and serum aldosterone concentration in patients with different types of renovascular hypertension**  
 N. Avdonina (Russia)
- 09:50–10:00 **General discussion**
- 10:00–11:00 **Obesity**  
 A. Cuevas (Chile), Z. Fras (Slovenia)
- 10:00–10:20 **Comprehensive management of obesity - an important present/future step in accomplishing our mission of CVD prevention**  
 Z. Fras (Slovenia)
- 10:20–10:40 **Bariatric surgery and cardiometabolic diseases**  
 A. Cuevas (Chile)
- 10:40–10:50 **The impact of bariatric surgery on cardiometabolic profile and adipokine levels**  
 F. Reis de Azevedo Rabello (Brazil)
- 10:50–11:00 **General discussion**
- 11:00–11:15 **Coffee break**

Thursday, June 2, 2016

Friday, June 3, 2016

Saturday, June 4, 2016

- 11:15-12:15**     **Genetics**  
M. Vrablik (Czech Republic), M. Voevoda (Russia)
- 11:15-11:25**     **Introduction**  
M. Vrablik (Czech Republic)
- 11:25-11:35**     **Analysis of risk factors and characteristics of genetic predisposition and clinical- angiographic manifestations of atherosclerosis in patient with ischemic organ damage without stenotic vascular damage**  
H. Shabalina (Russia)
- 11:35-11:45**     **A loss-of-function variant in OSBPL1A predisposes to low plasma HDL cholesterol levels and impaired cholesterol efflux capacity**  
V. Olkkonen (Finland)
- 11:45-11:55**     **Mitochondrial mutations and monocyte activation**  
A. Orekhov (Russia)
- 11:55-12:05**     **Single nucleotide polymorphisms at the hydroxy-methyl-glutaryl-coa reductase gene locus significantly predict cardiovascular events in coronary patients with type 2 diabetes**  
A. Leisherer (Austria)
- 12:05-12:15**     **PCSK9 regulates lipid metabolism, autophagy, and atherosclerosis**  
B.-B. Teng (USA)
- 12:15-12:30**     **Closing**  
R. Ceska (Czech Republic), Y. Matsuzawa (Japan), P. Barter (Australia), E. Shlyakhto (Russia), M. Ezhov (Russia)

## Meeting Hall MUNICH (2<sup>nd</sup> floor)

- 09:00-11:00**     **Symposium of the international task force for prevention of cardiometabolic diseases**  
**Diabetes and atherosclerosis: New translational aspects**  
G. Assmann (Germany), H. Greten (Germany)
- 09:00-09:30**     **Lipids and lipoproteins beyond LDL-cholesterol**  
A. von Eckardstein (Switzerland)
- 09:30-10:00**     **Epicardial fat and heart disorders**  
E. Baranova (Russia)
- 10:00-10:30**     **New lipid lowering strategies and implications for prevention**  
M. Tikkanen (Finland)
- 10:30-11:00**     **New glucose lowering drugs and role in recent CV outcome trials**  
D. Müller-Wieland (Germany)
- 11:00-11:15**     **Coffee Break**
- 11:15-12:15**     **Hot lines**  
R. Ceska (Czech Republic)